| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99284 |
Emergency department visit for the evaluation and management, high severity |
2,060 |
1,932 |
$423K |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
4,069 |
3,859 |
$233K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
535 |
505 |
$106K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
576 |
567 |
$45K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
963 |
874 |
$26K |
| 80053 |
Comprehensive metabolic panel |
2,399 |
2,097 |
$26K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
2,967 |
2,546 |
$19K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
382 |
378 |
$14K |
| 71045 |
Radiologic examination, chest; single view |
731 |
675 |
$13K |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
1,094 |
1,072 |
$13K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
200 |
194 |
$10K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
149 |
143 |
$7K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
47 |
44 |
$4K |
| 81001 |
|
1,216 |
1,132 |
$3K |
| 84484 |
|
564 |
432 |
$3K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
350 |
309 |
$3K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
62 |
61 |
$3K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
474 |
438 |
$2K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
137 |
131 |
$2K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
558 |
445 |
$2K |
| 84703 |
|
330 |
319 |
$2K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
40 |
38 |
$1K |
| 83690 |
|
383 |
359 |
$1K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
90 |
77 |
$520.05 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
542 |
472 |
$484.59 |
| 96361 |
Intravenous infusion, hydration; each additional hour |
82 |
74 |
$407.95 |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
200 |
168 |
$249.27 |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
48 |
40 |
$200.24 |
| 96376 |
|
14 |
12 |
$157.40 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
54 |
50 |
$63.93 |
| 80048 |
Basic metabolic panel (calcium, ionized) |
15 |
13 |
$53.66 |
| 85730 |
|
12 |
12 |
$45.37 |
| 86140 |
|
14 |
14 |
$43.60 |
| 85610 |
|
15 |
14 |
$32.40 |
| J2272 |
Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg |
13 |
12 |
$21.59 |
| 36415 |
Collection of venous blood by venipuncture |
814 |
733 |
$10.62 |
| A9270 |
Non-covered item or service |
564 |
504 |
$0.00 |